Trevi Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:TRVI) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -9.55 M-13.48 M-10.1 M-10.88 M-7.63 M -42.09 M Cash from investing activities -23.87 M-9.95 M-2.61 M-50.94 M-30.61 M -94.11 M Cash from financing activities 51.47 M8.71 M110.39 M1.63 M284 K 121.01 M Free cash flow -9.56 M-13.48 M-10.1 M-10.89 M-7.63 M -42.1 M

Haberler

Needham, Trevi Therapeutics için hedef fiyatı yükseltti

Cantor Fitzgerald, Trevi Therapeutics hissesi için Ağırlıklı Al tavsiyesini yineledi

Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript

Trevi Therapeutics 4Ç 2025 kazancı beklentileri aştı

Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion

Trevi Therapeutics hissesine Oppenheimer’dan Faz 3 planları sonrası destek

Trevi Therapeutics stock gets Oppenheimer nod on Phase 3 plans

Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March

Trevi, IPF’de kronik öksürük tedavisi için iki Faz 3 denemesi planlıyor

Trevi plans two phase 3 trials for chronic cough treatment in IPF

Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?

Trevi’nin nalbuphine ER ilacı IPF öksürüğünde önemli azalma gösterdi